Abstract

Tetra-arsenic tetra-sulfide (As4S4) is an arsenic compound with anti-tumor activity, especially in acute promyelocytic leukemia (APL) that are resistant to retinoic acid (RA). Although recent studies revealed that the therapeutic action of As4S4 is closely associated with the induction of cellular apoptosis, the exact molecular mechanism of action of As4S4 in RA-resistant APL remains to be clarified. In this study, we found that As4S4-induced apoptosis was accompanied by reduced mRNA and protein expression of SET gene in RA-resistant NB4-R1 cells. Moreover, RNAi knockdown of SET gene further promoted As4S4-induced apoptosis, while SET over-expression inhibited it, suggesting that As4S4 induces apoptosis through the reduction of SET protein in NB4-R1 cells. We also demonstrated that the knockdown of SET gene resulted in the upregulation of protein phosphatase 2 (PP2A) expression and the downregulation of promyelocytic leukemia and retinoic acid receptor α fusion gene (PML-RARα) expression, which were enhanced by As4S4 treatments. By contrast, over-expression of SET gene resulted in PP2A downregulation and PML-RARα upregulation, which were abolished by As4S4 pretreatment. Since PP2A is a pro-apoptotic factor and PMLRARα is an anti-apoptotic factor, our results suggest that As4S4-induced apoptosis in NB4-R1 cells is through the downregulation of SET protein expression, which in turn increases PP2A and reduces PML-RARα expressions to lead to cell apoptosis.

Highlights

  • Acute promyelocytic leukemia (APL), known as acute progranulocytic leukemia, is a subtype of acute myelogenous leukemia (AML)

  • The morphological changes of As4S4 on NB4-R1 cells To determine whether the inhibition of cell proliferation by MTT assay after treatment with As4S4 was attributed to the induction of cellular apoptosis, ultrastructural characteristics of the cells were evaluated by transmission electron microscopy (TEM)

  • Recent studies revealed that the therapeutic action of As4S4 is closely associated with the induction of cellular apoptosis [19,26,27,28], the definitive molecular mechanism of action of As4S4 in APL therapy still remains unknown

Read more

Summary

Introduction

Acute promyelocytic leukemia (APL), known as acute progranulocytic leukemia, is a subtype of acute myelogenous leukemia (AML). APL is a morphological M3 subtype of AML and is characterized cytogenetically by a reciprocal translocation between chromosomes 15 and 17, which results in the fusion gene of promyelocytic leukemia (PML) gene and retinoic acid receptor a (RAR a) gene [1,3]. This fusion protein, PML-RARa, binds with enhanced affinity to sites on the cellular DNA and enhances interaction of nuclear co-repressor (NCOR) molecule and histone deacetylase (HDAC), blocking transcription, differentiation of granulocytes, and inhibition of apoptosis [4,5]. Arsenic trioxide (As2O3 or ATO), with or without ATRA, has shown high efficacy and reduced hematologic toxicity in APL treatment and has been approved for the treatment of relapsed patients both in the United States and Europe [8]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call